Mobility paves Samsung’s silver path
The Korean giant’s early bet on mobile phones helped it hit the $10-bn mark in India, but in its 25th year it ...
The Centre’s concern to rollout a vaccine at the earliest and vaccinate 30 crore people in varying orders of priority is laudable. To this end, the Central Drugs Standard Control Organisation (CDSCO) has cleared for emergency use, the vaccines developed by Astra Zeneca-Oxford (made by Serum Institute of India) and Bharat Biotech (in collaboration with the Indian Council of Medical Research and National Institute of Virology). The assumption is that due diligence has been done while granting approval with respect to safety, efficacy and immunogenicity (capacity to trigger an immune response). Any early setback in the vaccine effort, particularly with respect to frontline workers, can derail confidence. While it is difficult to believe that the CDSCO has not satisfied itself about the safety of the vaccines before granting approval, it will certainly help if it is more transparent about the entire approval process. It is fair to argue that that the CDSCO could have taken more time to satisfy itself that the criteria for emergency use — benchmarking them more to the FDA norms than the New Drugs and Clinical Trial Rules, 2019 which follow loosely defined thresholds — have been met. Unlike in the West, India’s case load has been falling. Since September 15 when the daily count was about 84,000, the daily active cases in India have gone down to 18,177 as of January 3. In Tamil Nadu, the number of people testing positive dropped below the 900-mark on January 3, the first time since May 30. In Delhi, the daily count has gone down to 424 in the last 24 hours, the lowest in about eight months.
The clearances have raised questions that the Drugs Controller must address at the earliest. It is not clear if the Subject Expert Committee, on the basis of whose inputs the CDSCO has given its approval, has evaluated efficacy in either vaccine. In the case of the Oxford-Astra Zeneca vaccine it is not clear what data from the foreign trials were used to permit its usage here; likewise, the data on ‘bridging’ or equivalence trials in India, the very basis for rolling out the vaccine here, must also be shared. Similarly, Bharat Biotech does not seem to have produced data on the phase 3 trials being carried out on over 22,000 people. Given the sensitivity of the issue and the doubts raised by health experts, it is only fair to expect the regulator to clarify.
It is remarkable that India has a choice of vaccines, including several indigenous ones in various stages of development, to fall back on in such a short period of time. This is a tribute to capabilities built by the domestic pharmaceuticals industry over the years. While leveraging on this advantage for the benefit of the country it is imperative that due process is not only followed but also seen to be followed. This is not just about combating a disease but also about winning confidence of the people that the vaccines are safe to take.
The Korean giant’s early bet on mobile phones helped it hit the $10-bn mark in India, but in its 25th year it ...
Antrix should adopt a different tactic than merely fighting over jurisdiction: Experts
Invest in relationships, enterprise, behaviour, effort and learning
From different types of osmoses to new membranes, researchers have come up with ways of drawing water
Only half the Sensex stocks have bettered the index’s return in the last 10,000-point journey
High valuation and stiff competition from larger players are a dampener
Investors with a short-term perspective can buy The New India Assurance Company (NIACL) stock at current ...
₹1490 • HDFC Bank S1S2R1R2COMMENT 1475146015051520 Fresh short positions are recommended with a stiff ...
What makes the new crop of young Indian cricketers such game-changing winners? Over and above their talent, ...
Each new year millions of people around the world resolve to change their lives for the better. These ...
In these isolated times when people yearn for a slice of the familiar, amateur and professional chefs are ...
‘You ready to go to work?’ Joe Biden had asked Kamala Harris before naming her as his running mate. ‘Oh my ...
Digital is becoming dominant media, but are companies and their ad agencies transforming fast enough to make a ...
Slow Network, promoted by journalist-lyricist Neelesh Misra, pushes rural products and experiences
How marketers can use the traditional exchange of festive wishes meaningfully
For Fortune, a brand celebrating its 20th anniversary, it was a rude shock to become the butt of social media ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...